A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Sarilumab (Primary) ; Folic acid; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms MOBILITY; RA-MOBILITY; SARIL-RA-MOBILITY
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Results of pooled analysis from four studies (MOBILITY, TARGET, EXTEND and MONARCH) presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Long-term five year results from six clinical trials including this trial presented at the 19th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top